PHS46 Monthly Cost Of Therapy For Palliative Type Ii Diabetes In Mumbai: A Survey  by Thakur, TM & Majumdar, A
 VA L U E  I N  H E A LT H  1 7  ( 2 0 1 4 )  A 1 - A 2 9 5  A133
hospitalized for ≥ 2 days (hospitalized patients; HPs), or using emergency room (ER) 
or observation for 1 day (emergency room patients; ERPs). Reimbursements were 
based on claims and inflated to 2010 USD; costs were derived from 2010 Premier 
data. Net reimbursement was analyzed by MS-DRG and length of stay (LOS). The 
risk of all-cause hospitalization and factors correlated with LOS were determined 
using regression modeling. Results: Across all study years, the median age was 
71 for HPs, 65 for ERPs. Median Charlson Comorbidity Index (CCI) was 4 for HPs and 
2 for ERPs. HPs had more cellulitis on the leg or surgical infection; ERPs had more 
cellulitis on the face, trunk, or arm. Median HP LOS was 4 days; 33% of patients had 
LOS > 6 days. Age, race, and history of bacterial infection were correlated with LOS. 
Median all-cause, ABSSSI-related and index event costs during the index quarter 
for patients with a principle ABSSSI diagnosis were $9,930, $6,123 and $5,604 for 
HPs and $1,127, $108 and $100 for ERPs respectively. ConClusions: HPs were older 
and sicker than ERPs, with more cellulitis on the leg and post-operative infections. 
Further research and analysis may help determine whether treating some hospital-
ized patients with less comorbidity in the ambulatory setting might result in lower 
costs per patient after controlling for these factors.
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objeCtives: The aims of this study were to determine the clinical consequences 
and non-pharmacological costs of the usage of oral anticoagulation (OAC) therapy 
for the treatment of atrial fibrillation (AF) at EsSalud in Peru. Methods: A markov 
model was adapted to evaluate the clinical and economic impact of OAC on a cohort 
of 1,000 patients among the AF vitamin K antagonists (VKA) suitable population 
at EsSalud in Peru. Comparators for the analysis are: apixaban 5mg BID, warfarin 
5mg and aspirin 150mg. A lifetime horizon and EsSalud´s perspective were used. 
A discount rate of 3.5% was applied to both costs and outcomes. Efficacy data was 
taken from the clinical trials for apixaban, ARISTOTLE and AVERROES, which directly 
compared apixaban with warfarin and apixaban with aspirin, respectively. Resource 
utilization for each event was collected from a clinical chart review at a specialized 
care center of EsSalud. All costs were taken from EsSalud´s 2013 tarrifs and are 
expressed in 2013 US dollars. Results were validated by an expert panel of clinicians 
from EsSalud. Results: The number of events associated with each anticoagu-
lant therapy (apixaban, warfarin and aspirin respectively) were: stroke (ischemic 
and hemorrhagic) and systemic embolism 309, 352, 352, major bleedings 116, 149, 
102; and event related deaths 401, 447, 445, respectively. Apixaban was associated 
with a reduction of the non-pharmacological costs when compared with warfarin 
and aspirin in the range of $245 – $1,282. ConClusions: Over a lifetime horizon 
apixaban demonstrates a reduction in the number of AF complication events and 
reduction in non-pharmacological costs at EsSalud.
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objeCtives: To asses the costs and financial consequences of epidemiological 
changes for chronic diseases (HYPERTENSION AND DIABETES) in a middle-income 
country. Methods: An evaluative approach based on a longitudinal design was 
used. Direct costs were determined for the functions of production, standards of 
quality and the estimation of inputs costs. Indirect costs were determined by using a 
human capital model for Latin America which uses indicators of premature mortal-
ity and disability (temporary or permanent). Probabilistic models were developed 
to estimate epidemiological changes during 2010-2012 by using the Box-Jenkins 
technique. Finally, the economic burden was obtained for disease by applying an 
econometric adjustment factor. Results: Taking hypertension results, compar-
ing the economic impact in 2010 versus 2012 (p< 0.05), there is a 24% increase in 
financial requirements. The total amount for hypertension in 2011 (US dollars) was 
$ 5733,350,291. It include $ 2718,280,941 in direct costs and $ 3015,069,350. Costs for 
hypertension are permanently increasing in regards to economic burden, showing 
an increase of 33%. This average has differences for insured and uninsured popula-
tions. ConClusions: Health care systems and society in middle income countries 
will face important challenges on health financing, universal effective coverage and 
financial protection for the uninsured, if the risk factors and the health care model 
remain as currently are. The major economic impact of chronic diseases will be in 
users out of pocket expenditures because of indirect costs. We suggest an important 
reorganization of the planning process, the health care model and the allocation of 
resources mechanisms, in order to strengthen health care and access to hospital 
and outpatient services for patients suffering a chronic disease.
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objeCtives: Visual loss is significantly associated with increased risk of mortality 
and decreased quality of life. In Prince Edward Island (PEI), Canada, eye examination 
and cost of eyeglasses are not covered by provincial health insurance. This study 
aimed to assess the cost-effectiveness of insured eye examination compared to non-
insured eye examination for PEI residents. Methods: A cost-effectiveness analysis 
was conducted from a perspective of Canada’s health care system. A target popula-
tion was a PEI resident aged 42 years or older. Risk of vision loss and utility data were 
of care for different categories of patients including cost of health care provider time 
per visit, lab tests, ARV drugs and non ARV drugs. Results: The cost of treatment 
for an HIV positive patient with a CD4 count > 350 cells/ uL who has not started 
ART was $51/year. The cost of treating a patient on first line therapy in the first 
year of ART was $218, and thereafter $284/yr. The cost of a patient on second line 
ART was $1393/year. The cost of treatment of pregnant and patients co-infected 
with M. tuberculosis was $229/year and $413/year respectively. The costs are driven 
predominantly by ARV costs. ConClusions: This analysis shows the actual costs 
of HIV care at a larger urban HIV clinic in SSA. The increasing number of patients on 
second line ARVs is likely to dramatically increase the financial burden on health 
services in SSA in the future.
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objeCtives: Approaches for predicting cost accumulation for heterogeneous 
samples are limited. We employ the Grouping Algorithm for Cancer Cost Data 
(GACCD) to investigate cost accumulation over time and identify ‘high cost’ 
patients. Methods: Two-fold cross validation was used to evaluate survival and 
cost accumulation using linked prostate cancer (PCa) registry and Medicare claims 
data from 1999-2009. Patients were grouped according to a refined similarity metric 
using five patient characteristics (cancer stage, age, Charlson Comorbidity Index 
(CCI), performance proxy indicator, race). Cost accumulation was evaluated in the 
test dataset for the GACCD groups identified in the training data. Curves using the 
test data plotted inverse probability weighted cumulative average total monthly 
costs (CATMC) for the post-diagnosis period and the proportion of people who were 
deemed to be ‘high cost’. Results: Application of the inclusion criteria resulted in 
110,824 patients. Median (mean) follow up was 48 (51) months and the mortality rate 
was 27.3%. The five GACCD groups had distinguishing characteristics e.g., group2 
patients were typically older, with CCI above 2 and/or diagnosed with either later 
stage or unstaged PCa; group3 patients were typically younger, with CCI= 0 and diag-
nosed with early stage PCa. Cost accumulation within the first three years varied 
across the groups, with the lowest (highest) rate in group3 (group2) in the training 
dataset. Using the test data: at a threshold of $10,000 in CATMC, the proportion of 
patients that was high cost within three years following diagnosis ranged from 
82% in group3 to 90% in group2; proportions ranged from 45% in group3 to over 
60% in group2 at a threshold of $25,000; proportions ranged from 15% in group3 to 
over 30% in group2 at a threshold of $50,000. ConClusions: A grouping algorithm 
with a refined similarity metric can identify patient subgroups that will accumulate 
higher costs over time.
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objeCtives: (1)Survey to estimate the monthly expenditure of a Type II Diabetes 
patient in Mumbai . (2)To project the fact that even in absence of health insurance 
policies by government for its citizens, patients receive free or cost subsidized treat-
ment in the government hospitals. (3)Explore government initiatives in regulating 
the price of the Diabetes II drugs. Methods: Three sets of structured question-
naires were designed which captured the patient demographics,prescription trends 
of type II Diabetes patients in Mumbai,India.The survey through questionnaires tar-
geted three government secondary hospitals,two government tertiary hospitals,35 
General Practioners,50 Drug stores. Results: (1) 46%of the patients detected with 
type II Diabetes lie in the age group of 50-60 years. (2)Amongst them the population 
of males affected is little more than females ie.51% males vs 46% females. (3)The 
trend of drugs as prescribed by the General Practioners is same as that of drug pre-
scriptions received by drug stores.The Metformin containing generic brands which 
fall under The Drug Price Control Order(DPCO) 2013 (cap price removed)is majorly 
prescribed followed by glypizides , acarbose and pioglitazone containing generic 
brands. ConClusions: : (1)The monthly expenditure of a Type II Diabetes patient in 
Mumbai is Rs.300 (USD 4.8)when the patient is treated by GP and purchases the drug 
from the drug stores. (2)The patients are either treated free or in subsidized rates 
in government hospitals.ie.in 2.4USD per month. (3)The metformin category drugs 
coming under DPCO 2013 are the majorly prescribed drugs. Thus it is very easy and 
convenient for type II Diabetes patients in Mumbai to suffice their medical needs in 
the most reasonable and affordable price and also get free treatment from tertiary 
government hospitals.Although a federal/government health insurance policy does 
not exist in India the government through its subsidies or free treatments rightly 
makes this therapy accessible to the common man of the city.
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objeCtives: Recent clinical trials of antibiotics targeted to ABSSSI have included 
large proportions of patients treated in the ambulatory setting. An objective of 
this study of real-world patient transaction data was to analyze differences 
between Medicare patients treated in the inpatient versus the ambulatory set-
ting. Methods: Analysis used Medicare 5% Limited Data Set (LDS) files contain-
ing claims for 27,607 patients age ≥ 18 with a principal diagnosis of ABSSSI between 
Q4, 2007 – Q3, 2010 from a 5% sample of Medicare beneficiaries, including patients 
